Drug Topics
SEPTEMBER 10, 2024
Researchers explored an alternative pharmacist education intervention as a way of improving pharmacist-patient conversations and decreasing vaccine hesitancy among patients.
Pharmacy Times
SEPTEMBER 10, 2024
To help with treatment response and compliance as well as optimize treatment, communication between patients and health care providers is necessary.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
SEPTEMBER 10, 2024
Data from the SELECT clinical trial were analyzed to evaluate the role of semaglutide therapy on all-cause, cardiovascular, and non-cardiovascular mortality during the COVID-19 pandemic.
Fierce Healthcare
SEPTEMBER 10, 2024
Half of women in the U.S. skip or delay medical care due to the “triple threat” of affordability, access challenges and past negative experiences, a new Deloitte report finds. | The Deloitte report, based on a survey of more than 2,000 consumers, found that 50% of women report skipping or delaying medical care and are 35% more likely to skip care than men.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
SEPTEMBER 10, 2024
The #MyCRChistory campaign encourages the public to share their family history of colorectal cancer.
STAT
SEPTEMBER 10, 2024
Amid calls to expand access to medicines in low- and middle-income countries, a new analysis finds that most of the world’s 20 largest pharmaceutical companies have taken steps to reach patients, but many efforts are yielding decidedly mixed results. On the one hand, 19 companies have established methods for providing treatments to these countries — but only nine of the drugmakers created comprehensive plans.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
SEPTEMBER 10, 2024
The first late-stage trial of a GLP-1 drug in young children with obesity showed the treatment helped lower body mass index. But the findings also raise questions about whether obesity medications, some of which are currently approved for teenagers, should also be given to children at such a young age. The 56-week trial tested Novo Nordisk’s Saxenda, the predecessor of Wegovy, coupled with lifestyle interventions in children ages 6 to 12.
Fierce Healthcare
SEPTEMBER 10, 2024
Over 300 organizations sent letters to the White House and Congress on Tuesday asking them to extend telehealth controlled substance prescribing rules for an additional two years. | Stakeholders that support the prescription of all controlled substances via telehealth are fighting an uphill battle to get the pandemic-era prescribing flexibilities extended.
STAT
SEPTEMBER 10, 2024
Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates that may be more effective than Wegovy. In a Phase 1 trial, a 50-mg dose of the daily pill called amycretin, which activates receptors of both the amylin and GLP-1 hormones, led to 10.4% weight loss at about three months after the start of treatment.
Fierce Pharma
SEPTEMBER 10, 2024
After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold. | Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
SEPTEMBER 10, 2024
PROVIDENCE, R.I. — In a cavernous converted chapel at Brown University, physician and data scientist Leo Celi observed from the sidelines as a tableful of high school students passed around a plastic, crocodilian device. The pulse oximeter clamped down on one student’s fingertip: Ninety-seven, he read out loud, before handing it off to the student next to him.
Pharmacy Times
SEPTEMBER 10, 2024
Breanne Peyton-Thomas, PharmD, BCOP, discusses her work as a pharmacist at Ochsner Health on the CAR T-cell therapy team.
STAT
SEPTEMBER 10, 2024
Two former Verily executives say that they are starting a new initiative, Highlander Health, to push forward an effort decades in the making: making it so that the records collected in hospitals can be used in real-time to advance science, decreasing the cost of conducting clinical trials and speeding medical progress while helping patients get the right drug for them.
Fierce Healthcare
SEPTEMBER 10, 2024
Habitat Health, an organization founded last year to provide care support to older adults at home, secured $50 million in capital from investors Town Hall Ventures, New Enterprise Associates and Ka | Habitat Health, an organization founded last year to provide care support to older adults at home, secured $50 million in capital from investors Town Hall Ventures, New Enterprise Associates and Kaiser Permanente.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
SEPTEMBER 10, 2024
Seven years after the FDA approved Luxterna , scientists have yet to bring another congenital blindness treatment to the market. A team of researchers from the Perelman School of Medicine at the University of Pennsylvania aims to change this. The group recently published a study in The Lancet documenting their success using gene therapy to treat an inherited retinal blindness that affects as many as 100,000 people globally.
Drug Topics
SEPTEMBER 10, 2024
Data from the SWIFT-1 and SWIFT-2 studies were presented by GSK at the European Respiratory Society International Conference.
STAT
SEPTEMBER 10, 2024
For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the next drug it planned to buy with some of the $6 billion made from last year’s Roche deal. On Tuesday, Gline obliged. Roivant has acquired from Bayer, the German pharma company, an experimental drug called mosliciguat that will be developed as a treatment for certain types of pulmonary hypertension, a family of serious lung diseases in which high blood pressure affects the arteries in the lungs
Fierce Healthcare
SEPTEMBER 10, 2024
After 128 physician group faculty signed on to a letter of no confidence in the heads of the University of Virginia’s (UVA's) health system and medical school, the institution’s president has promi | Over 100 anonymous faculty called for "the immediate removal" of UVA Health CEO Craig Kent, M.D., and UVA School of Medicine Dean Melina Kibbe, M.D.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
SEPTEMBER 10, 2024
What does it cost to have a baby in the United States? This question has always vexed me. I’ve tried unsuccessfully to prospectively price deliveries for family and friends over the years. After insurance, deliveries can range from a few hundred dollars to a couple of thousand. If you’re underinsured or have a more complex birth, it can cost more than $10,000 out of pocket.
pharmaphorum
SEPTEMBER 10, 2024
Investment in life sciences real estate is booming as the industry faces the looming 'patent cliff' Learn about the current trends and what lies ahead for this sector.
STAT
SEPTEMBER 10, 2024
This is Part 4 of “ Behind the Counter ,” an in-depth video series demystifying the complex world of patents and drug pricing. Years ago, when a brand-name medication’s patent expired, consumers had to wait a long time for a more affordable generic version to come to market. But in 1984, a little-known law put an end to that waiting period and paved the way for the large quantity of generic drugs available today.
The Checkup by Singlecare
SEPTEMBER 10, 2024
An estimated 8% of Americans get the flu each year, according to the Centers for Disease Control and Prevention (CDC). If you’ve ever been suddenly sidelined by influenza, you’ve experienced the misery of being completely drained—too weak to even get out of bed. As you wait for the debilitating flu infection to run its course, you’d do anything to speed up the process.
STAT
SEPTEMBER 10, 2024
WASHINGTON – Powerful House lawmakers from both parties are skeptical of the Food and Drug Administration’s pitch to start collecting fees from e-cigarette companies, similar to how the agency assesses them on tobacco firms. FDA officials say that the fees, which e-cigarette companies would pay when filing applications with the agency, would give regulators resources to tackle the thousands of illegal vapes lining store shelves.
Pharmaceutical Technology
SEPTEMBER 10, 2024
Baltimore opted out of a national settlement last year, instead pursuing its own claim against the opioid manufacturer.
STAT
SEPTEMBER 10, 2024
Elevance Health, the parent of more than a dozen state Blue Cross Blue Shield plans, is purchasing Indiana University Health’s insurance business in a deal that would increase its dominance in several key cities in the state. IU Health’s decision to sell is the latest and most prominent example of hospital systems giving up on the idea that they can be both a provider and payer of care.
Pharmaceutical Commerce
SEPTEMBER 10, 2024
The latest news for pharma industry insiders.
STAT
SEPTEMBER 10, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Flare Capital ‘s new examination of 4,000 healthcare AI venture capital deals looked at where investment has actually created value — that is, what early-stage, venture-backed technology matures enough to impact the health care ecosystem?
Pharmaceutical Commerce
SEPTEMBER 10, 2024
A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.
STAT
SEPTEMBER 10, 2024
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on Wednesday, bringing the firms closer to securing Food and Drug Administration approval after the agency rejected their application last year. In the Phase 3 trial, dubbed Liberty-Cupid Study C, patients took antihistamines, the current standard of care, and Dupixent or a placebo.
PioneerRx
SEPTEMBER 10, 2024
ER prescriptions requires a different kind urgency and attention to detail compared to maintenance medications — so let’s get on the right foot.
STAT
SEPTEMBER 10, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Hello, happy Tuesday. Temperatures are projected to be in the 50s every morning this week in Boston, per a glance at my phone. Is it officially fall? Where can I get a good apple cider donut? What stories should we report before the end of the year creeps up on us?
PharmaVoice
SEPTEMBER 10, 2024
Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health.
Pharmaceutical Technology
SEPTEMBER 10, 2024
The study involved over 3,600 participants, including FDRs of newly diagnosed type 1 diabetes patients in Denmark and children in Sweden.
Expert insights. Personalized for you.
201 
Let's personalize your content